← Back to headlines
H.C. Wainwright Maintains Buy Rating on Allogene Therapeutics
H.C. Wainwright has reiterated its 'Buy' rating for Allogene Therapeutics (ALLO), indicating a positive outlook on the company's stock.
23 Apr, 07:30 — 23 Apr, 07:30
Sources
Showing 1 of 1 sources
Related Stories
Signet Jewelers Raises Profit Forecast After Strong Quarterly Results
46m ago
Nigeria’s Oil Regulator Threatens Permit Revocations for Idle Gas Flare Sites
1h ago
Record Travel Demand Hits Dublin Airport and Portuguese Cruise Industry
1h ago
Corporate Earnings Highlights from Wells Fargo and Goldman Sachs Conferences
1h ago